CEP re-granted

Through continuous technological R&D and innovation, in February 2025, our company has once again obtained the Certificate of Suitability to the European Pharmacopoeia (CEP) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). This renewed CEPreaffirms Suzhou Tianlu's robust capabilities in the field of Ursodeoxycholic Acid. Following the initial CEPin 2011, this achievement marks another significant breakthrough for the company, demonstrating that the product quality, production processes, and management systems continue to earn authoritative international recognition. This milestone lays a solid foundation for deepening the company's presence in the European market, enabling the delivery of high-quality products to meet the demands of European and global markets.